GlassScriptPhysician profile
Claudia Hoefferle
NPI 1790106516
$3,179.24
in general payments reported to CMS, 2019-2025
22 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $331 · 2022: $377 · 2023: $989 · 2024: $1,033 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,334 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.25 |
| Education | $137.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $568.25 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Dexcom, INC. | $521.74 | 2021-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Abbott Laboratories | $423.03 | 2022-2025 | Freestyle Libre 2 |
| Lilly USA, LLC | $282.71 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Tandem Diabetes Care, INC. | $258.93 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Medical Device Business Services, INC. | $137.01 | 2025 | Stratafix |
| Bayer Healthcare Pharmaceuticals INC. | $128.79 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $124.93 | 2023-2024 | Gvoke Hypopen |
| Amgen INC. | $122.17 | 2021-2024 | Repatha, Evenity, Tepezza |
| Insulet Corporation | $99.28 | 2021-2022 | |
| Medtronic, INC. | $76.94 | 2021-2024 | Minimed 780g, Minimed 770g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.33 | 2023-2024 | Jardiance |
| Beta Bionics, INC. | $71.24 | 2023-2024 | Ilet Bionic Pancreas |
| Novartis Pharmaceuticals Corporation | $68.28 | 2023-2024 | |
| Lifescan, INC. | $39.98 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $35.89 | 2024 | Korlym |
| Exact Sciences Corporation | $29.66 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $27.26 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $23.47 | 2021 | |
| Sanofi-Aventis U.S. LLC | $22.82 | 2023 | |
| Ascensia Diabetes Care US INC. | $20.34 | 2024 | |
| Ibsa Pharma INC. | $20.19 | 2024 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Hoefferle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.